Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.75 +0.5%	$0.75	$0.56 ▼ $6.89	$12.31M	0.6	1.40 million shs	1.04 million shs
NNVC NanoViricides	$1.55 +3.0%	$1.51	$0.94 ▼ $2.34	$24.83M	0.96	244,796 shs	187,970 shs
RXII RXi Pharmaceuticals	$2.18 -0.5%	$0.42	$0.31 ▼ $7.70	$9.55M	2.07	1.73 million shs	173,048 shs
TAOX Synaptogenix	$8.69 +3.5%	$0.00	$1.84 ▼ $11.98	$12.08M	1.87	434,456 shs	182,357 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	0.00%	+24.74%	+1.40%	-7.27%	-57.89%
NNVC NanoViricides	0.00%	-5.06%	-10.71%	+2.74%	-30.88%
RXII RXi Pharmaceuticals	0.00%	-3.11%	-10.29%	+18.48%	-26.85%
TAOX Synaptogenix	0.00%	+36.36%	+839,999,900.00%	+839,999,900.00%	+839,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBIO iBio	1.1856 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6
NNVC NanoViricides	0.3065 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.0
RXII RXi Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBIO iBio	3.00	Buy	$5.00	571.14% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
RXII RXi Pharmaceuticals	0.00	N/A	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RXII, NNVC, TAOX, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBIO iBio	$375K	32.82	N/A	N/A	$1.41 per share	0.53
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
RXII RXi Pharmaceuticals	$10K	954.84	N/A	N/A	$0.77 per share	2.83
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
RXII RXi Pharmaceuticals	-$12.45M	-$4.20	N/A	N/A	N/A	-4,990.20%	-412.15%	-179.54%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-359.08%	-153.14%	N/A

Latest RXII, NNVC, TAOX, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBIO iBio	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
RXII RXi Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBIO iBio	0.05	1.76	1.76
NNVC NanoViricides	N/A	3.44	2.47
RXII RXi Pharmaceuticals	N/A	1.77	1.77
TAOX Synaptogenix	N/A	72.59	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBIO iBio	7.90%
NNVC NanoViricides	10.30%
RXII RXi Pharmaceuticals	9.64%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
IBIO iBio	0.58%
NNVC NanoViricides	4.60%
RXII RXi Pharmaceuticals	1.01%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
RXII RXi Pharmaceuticals	N/A	4.38 million	N/A	Not Optionable
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A

RXII, NNVC, TAOX, and IBIO Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXII, NNVC, TAOX, and IBIO Company Descriptions

iBio NYSE:IBIO

$0.74 +0.00 (+0.51%)

As of 03:19 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

NanoViricides NYSE:NNVC

$1.54 +0.05 (+3.00%)

As of 03:21 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

RXi Pharmaceuticals NASDAQ:RXII

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Synaptogenix NASDAQ:TAOX

$8.69 +0.29 (+3.45%)

As of 03:02 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time